EmeseZsirosMDPhD, FACOG
Obstetrics & Gynecology • Buffalo, NYGynecologic Oncology, Minimally Invasive / Endoscopic Surgery
Associate Professor of Oncology
Dr. Zsiros is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-7608
Summary
- Dr. Emese Zsiros is a gynecologic oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. She received her medical degree from University of Debrecen Medical and Health Science Center in Hungary, completed her Ob/GYN residency at Northwestern University in Chicago and her fellowship in Gynecologic Oncology at the University of Pennsylvania. She has been in practice 12 years. She also speaks multiple languages, including Hungarian and Spanish. She specializes in gynecologic oncology and minimally invasive / endoscopic surgery and is experienced in gynecologic oncology, tumor immunotherapy, clinical research, minimally invasive gynecologic surgery, and adoptive immunotherapy.
Education & Training
University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2011 - 2013
McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 2007 - 2011
University of Debrecen Medical and Health Science CenterClass of 2005
Certifications & Licensure
NY State Medical License 2014 - 2025
PA State Medical License 2011 - 2016
IL State Medical License 2010 - 2011- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2016 Sep 01
- Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2017 Jun 27
- Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2023 Dec 15
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer.Spencer R Rosario, Mark D Long, Shanmuga Chilakapati, Eduardo Cortes Gomez, Sebastiano Battaglia
Nature Communications. 2024-12-05 - NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham
Journal of the National Comprehensive Cancer Network. 2024-10-01 - 8 citationsA phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.Sara Bobisse, Valentina Bianchi, Janos L Tanyi, Apostolos Sarivalasis, Edoardo Missiaglia
Nature Cancer. 2023-10-01
Press Mentions
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian CancerDecember 12th, 2024- NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024September 16th, 2024
- More Evidence to Support Restrictive Opioid Prescribing After Cancer SurgeryJanuary 6th, 2023
- Join now to see all
Professional Memberships
- Fellow
- Member
- Society of Gynecologic OncologyMember
- Member
- Member
Other Languages
- Hungarian, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
